Table 1.
Characteristics of the described studies.
| Study | Type of patient | Patients* (n°) | Treg identification | Treg or Foxp3 expression | Characteristic |
|---|---|---|---|---|---|
| Muthukumar et al. (2005) [34] | KT with AR | 36 | Foxp3 mRNA in urine | Elevated | Survival rate graft |
| Veronese et al. (2007) [35] | KT with AR | 59 | Foxp3 CD4+ in kt | Elevated | Survival rate graft |
| Bunnag et al. (2008) [36] | KT with AR | 31 | Foxp3 mRNA in kt | Elevated | Survival rate graft |
| Aquino-Dias et al. (2008) [37] | KT with AR | 20 | Foxp3 mRNA in kt, PBL, urine |
Elevated | Diagnosis of AR |
| Mansour et al. (2008) [38] | KT with BL changes | 46 | Foxp3 mRNA in kt | Reduced in PG | Outcome of BL changes |
| Xu et al. (2012) [39] | KT | 125 | Foxp3-positive T lymphocytes in kt | Elevated in RPG | Outcome of graft |
| Chung et al. (2012) [40] | KT with AR | 56 | Foxp3/IL-17 secreting cells ratio in kt | Elevated (in SRGa) | Survival rate graft |
| San Segundo et al. (2012) [41] | KT | 90 | Foxp3 CD4+ CD25+ in PBL | Elevated (in SRGa) | Survival rate graft |
*The number of patients does not refer to the total number of patients in each study, but to the subpopulation considered.
KT: kidney transplantation; AR: acute rejection; kt: kidney tissue; PBL: peripheral blood lymphocytes; BL changes: borderline changes; PG: progressive group; RPG: regulatory phenotype group; SRGa: patients with augmented survival rate graft.